DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED)

Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hepatitis C, Chronic

Intervention: Peginterferon alfa-2b (SCH 54031) (Biological); Ribavirin (SCH 18908) (Drug)

Phase: N/A

Status: Completed

Sponsored by: Merck Sharp & Dohme Corp.


The study is designed as a retrospective data review of medical records from participants selected from specialist secondary and tertiary care centers across the United Kingdom (UK), specializing in Hepatitis C treatment. The study is non-interventional and is designed to identify subgroups of Hepatitis C Virus (HCV) genotype 1 participants in the 'real world', including the relation between subgroup characteristics and treatment responsiveness.

Clinical Details

Official title: Retrospective Data Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol

Study design: Observational Model: Cohort, Time Perspective: Retrospective

Primary outcome: Participants With Treatment Success

Detailed description: Physicians will record information (from the time of first exposure to pegylated interferon alfa-2b and ribavirin) from the medical notes of participants who fit the inclusion criteria. To prevent selection bias, data are to be taken from the latest consecutive, unique participants seen by the physician over the previous 48 months. This provides a method of random sampling from a physician practice.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Participants with genotype 1 HCV infection who have been treated with pegylated

interferon alfa-2b and ribavirin in the preceding 48 months will be included. They will be divided into:

- Completer participants: Patients with a diagnosis of HCV genotype 1 who have

completed a course of interferon alfa-2b and ribavirin, with no prior treatment for HCV (ie, previously treatment naïve). Completer participants must have at least 24 weeks of follow up data available post completion of treatment to ensure ability to assess SVR rates.

- Early terminators: Participants who have terminated treatment early due to adverse

events or other reasons (ie, exposure is incomplete). Exclusion Criteria:

- Participants currently undergoing therapy and therefore have not terminated

treatment, ie, exposure is still ongoing.

- Co-infected HCV participants (eg, human immunodeficiency virus [HIV] or hepatitis B

virus [HBV]).

- Participants who received their first HCV treatment in relation to a clinical trial.

Locations and Contacts

Additional Information

Starting date: November 2007
Last updated: October 31, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017